Voya Investment Management LLC Sells 69,808 Shares of Halozyme Therapeutics, Inc. $HALO

Voya Investment Management LLC lessened its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 60.1% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 46,250 shares of the biopharmaceutical company’s stock after selling 69,808 shares during the period. Voya Investment Management LLC’s holdings in Halozyme Therapeutics were worth $3,392,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the company. Wealth Preservation Advisors LLC acquired a new stake in Halozyme Therapeutics during the 1st quarter worth approximately $32,000. Newbridge Financial Services Group Inc. acquired a new stake in shares of Halozyme Therapeutics during the second quarter worth $32,000. Employees Retirement System of Texas acquired a new stake in shares of Halozyme Therapeutics during the second quarter worth $34,000. Asset Management One Co. Ltd. bought a new stake in shares of Halozyme Therapeutics in the second quarter valued at about $98,000. Finally, EverSource Wealth Advisors LLC grew its stake in shares of Halozyme Therapeutics by 6.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock valued at $140,000 after acquiring an additional 174 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $75.35, for a total transaction of $1,507,000.00. Following the completion of the transaction, the chief executive officer owned 733,719 shares of the company’s stock, valued at approximately $55,285,726.65. The trade was a 2.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Cortney Caudill sold 4,263 shares of the firm’s stock in a transaction that occurred on Saturday, November 1st. The shares were sold at an average price of $65.19, for a total transaction of $277,904.97. Following the completion of the sale, the chief operating officer owned 12,737 shares in the company, valued at approximately $830,325.03. The trade was a 25.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 85,661 shares of company stock worth $6,036,837 over the last 90 days. Insiders own 2.40% of the company’s stock.

Analysts Set New Price Targets

HALO has been the subject of several analyst reports. Weiss Ratings reiterated a “hold (c+)” rating on shares of Halozyme Therapeutics in a research note on Monday. HC Wainwright reiterated a “buy” rating and issued a $90.00 price target on shares of Halozyme Therapeutics in a research report on Friday, December 19th. Morgan Stanley reduced their price target on Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating on the stock in a research report on Monday, October 20th. The Goldman Sachs Group restated a “sell” rating and set a $56.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, December 4th. Finally, Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Tuesday, November 4th. Six research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $75.10.

Halozyme Therapeutics Stock Up 0.7%

Shares of HALO opened at $68.87 on Friday. The firm has a 50 day simple moving average of $67.34 and a two-hundred day simple moving average of $65.41. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.59 and a quick ratio of 1.37. Halozyme Therapeutics, Inc. has a one year low of $47.50 and a one year high of $79.50. The company has a market cap of $8.10 billion, a P/E ratio of 14.50, a P/E/G ratio of 0.37 and a beta of 0.95.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.63 by $0.09. Halozyme Therapeutics had a return on equity of 156.95% and a net margin of 47.91%.The company had revenue of $354.26 million for the quarter, compared to analyst estimates of $339.18 million. During the same quarter last year, the company posted $1.27 EPS. The company’s revenue for the quarter was up 22.1% compared to the same quarter last year. Research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.